US20070213290A1
(en)
*
|
1996-10-17 |
2007-09-13 |
Kingsman Alan J |
Neurite regeneration
|
ES2153654T3
(es)
*
|
1996-10-17 |
2001-03-01 |
Oxford Biomedica Ltd |
Vectores retrovirales.
|
US7198784B2
(en)
*
|
1996-10-17 |
2007-04-03 |
Oxford Biomedica (Uk) Limited |
Retroviral vectors
|
JP4312265B2
(ja)
*
|
1997-04-09 |
2009-08-12 |
ラング−ジ チャン |
ワクチン評価のための動物モデル
|
AU741747B2
(en)
*
|
1997-05-13 |
2001-12-06 |
University Of North Carolina At Chapel Hill, The |
Lentivirus-based gene transfer vectors
|
US5994136A
(en)
*
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
US6121021A
(en)
*
|
1997-12-16 |
2000-09-19 |
Connaught Laboratories Limited |
Constitutive expression of non-infectious HIV-like particles
|
CN1322137C
(zh)
*
|
1997-12-22 |
2007-06-20 |
牛津生物医学(英国)有限公司 |
基于马传染性贫血病毒(eiav)的逆转录病毒载体
|
GB9803351D0
(en)
|
1998-02-17 |
1998-04-15 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
AU3988799A
(en)
|
1998-05-13 |
1999-11-29 |
Genetix Pharmaceuticals, Inc. |
Novel lentiviral packaging cells
|
AU4830899A
(en)
|
1998-06-24 |
2000-01-10 |
Musc Foundation For Research Development |
Tissue-specific and target rna-specific ribozymes
|
US6958226B1
(en)
|
1998-09-11 |
2005-10-25 |
The Children's Medical Center Corp. |
Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
|
GB9906177D0
(en)
|
1999-03-17 |
1999-05-12 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
US7250299B1
(en)
*
|
1999-04-29 |
2007-07-31 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
AU1013601A
(en)
|
1999-10-22 |
2001-05-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
CN1321182C
(zh)
*
|
1999-12-30 |
2007-06-13 |
卫生部艾滋病预防与控制中心 |
马传染性贫血病毒代表毒株的全基因克隆及其应用
|
EP1702983A3
(en)
|
2000-04-13 |
2007-01-10 |
Medical University of South Carolina |
Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof
|
CA2408328C
(en)
|
2000-05-10 |
2012-04-17 |
Aventis Pasteur Limited |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
US6627442B1
(en)
*
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
GB0024550D0
(ja)
|
2000-10-06 |
2000-11-22 |
Oxford Biomedica Ltd |
|
US7575924B2
(en)
|
2000-11-13 |
2009-08-18 |
Research Development Foundation |
Methods and compositions relating to improved lentiviral vectors and their applications
|
CA2344208A1
(en)
|
2001-04-30 |
2002-10-30 |
Oxford Biomedica (Uk) Limited |
Method
|
WO2002087341A1
(en)
*
|
2001-05-01 |
2002-11-07 |
Genetix Pharmaceuticals, Inc. |
Novel self-inactivating (sin) lentiviral vectors
|
EP1409025B1
(en)
|
2001-06-29 |
2011-11-30 |
Sloan Kettering Institute For Cancer Research |
Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies
|
DK1412493T3
(da)
|
2001-08-02 |
2012-01-09 |
Inst Clayton De La Rech |
Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer
|
IL161229A0
(en)
|
2001-10-02 |
2004-09-27 |
Inst Clayton De La Rech |
Methods and compositions relating to restricted expression lentiviral vectors and their applications.
|
DK2348119T3
(en)
|
2002-02-01 |
2017-08-21 |
Oxford Biomedica (Uk) Ltd |
Polycistronic lentiviral vector
|
GB0221778D0
(en)
*
|
2002-09-19 |
2002-10-30 |
Molmed Spa |
Conjugate
|
CN1759182A
(zh)
*
|
2002-11-22 |
2006-04-12 |
克雷顿研究院 |
调节基因的组合物和系统
|
EP1606419A1
(en)
|
2003-03-18 |
2005-12-21 |
Quantum Genetics Ireland Limited |
Systems and methods for improving protein and milk production of dairy herds
|
US7468273B2
(en)
|
2003-05-01 |
2008-12-23 |
Meial Limited |
Canine GHRH gene, polypeptides and methods of use
|
GB0325379D0
(en)
*
|
2003-10-30 |
2003-12-03 |
Oxford Biomedica Ltd |
Vectors
|
MXPA06005424A
(es)
|
2003-11-13 |
2007-01-25 |
Univ Georgia Res Found |
Metodos para caracterizar virus de enfermedad bursal infecciosa.
|
MXPA06009452A
(es)
|
2004-02-19 |
2007-03-15 |
Univ Alberta |
Polimorfismos del promotor de leptin y sus usos.
|
CA2561565C
(en)
*
|
2004-04-08 |
2013-11-26 |
Sangamo Biosciences, Inc. |
Methods for repression of phospholamban gene and modulating cardiac contractility
|
CA2561714A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathic and neurodegenerative conditions
|
JP2007535329A
(ja)
*
|
2004-04-29 |
2007-12-06 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
細胞接着性を増強する方法および組成物
|
FR2870126B1
(fr)
|
2004-05-17 |
2009-07-17 |
Pasteur Institut |
Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
|
PT1881845E
(pt)
|
2005-04-25 |
2010-05-31 |
Merial Ltd |
Vacinas de vírus nipah
|
US20060292159A1
(en)
*
|
2005-06-08 |
2006-12-28 |
Ranscht Barbara E |
Methods for the inhibition of neovascularization and cancer metastasis
|
US20080241184A1
(en)
|
2005-08-25 |
2008-10-02 |
Jules Maarten Minke |
Canine influenza vaccines
|
US7771995B2
(en)
|
2005-11-14 |
2010-08-10 |
Merial Limited |
Plasmid encoding human BMP-7
|
EP2186823A1
(en)
|
2005-11-14 |
2010-05-19 |
Merial Limited |
Gene therapy for renal failure
|
GB0526210D0
(en)
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Vectors
|
US7862821B2
(en)
|
2006-06-01 |
2011-01-04 |
Merial Limited |
Recombinant vaccine against bluetongue virus
|
WO2008134879A1
(en)
|
2007-05-04 |
2008-11-13 |
University Health Network |
Il-12 immunotherapy for cancer
|
CA2699394C
(en)
|
2007-09-17 |
2020-03-24 |
The Regents Of The University Of California |
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
|
JP2011503207A
(ja)
|
2007-11-16 |
2011-01-27 |
サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション |
循環系細胞におけるpim−1活性を操作するための組成物および方法
|
WO2009079373A2
(en)
*
|
2007-12-14 |
2009-06-25 |
The Regents Of The University Of California |
Inhibitors of calcium-activated chloride channels
|
US9169491B2
(en)
|
2008-06-18 |
2015-10-27 |
Oxford Biomedica (Uk) Limited |
Virus purification
|
CN103585643A
(zh)
|
2009-04-03 |
2014-02-19 |
梅里亚有限公司 |
运载新城疫病毒的禽疫苗
|
JP5965392B2
(ja)
|
2010-05-28 |
2016-08-03 |
オックスフォード バイオメディカ (ユーケー) リミテッド |
脳へのレンチウイルスベクターの送達
|
WO2012030720A1
(en)
|
2010-08-31 |
2012-03-08 |
Merial Limited |
Newcastle disease virus vectored herpesvirus vaccines
|
WO2012090073A2
(en)
|
2010-12-30 |
2012-07-05 |
The Netherlands Cancer Institute |
Methods and compositions for predicting chemotherapy sensitivity
|
EP2694677A2
(en)
|
2011-04-04 |
2014-02-12 |
Netherland Cancer Institute |
Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
|
AU2012240246A1
(en)
|
2011-04-04 |
2013-05-09 |
Netherlands Cancer Institute |
Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
|
WO2012145577A1
(en)
|
2011-04-20 |
2012-10-26 |
Merial Limited |
Adjuvanted rabies vaccine with improved viscosity profile
|
WO2012149038A1
(en)
|
2011-04-25 |
2012-11-01 |
Advanced Bioscience Laboratories, Inc. |
Truncated hiv envelope proteins (env), methods and compositions related thereto
|
WO2012166493A1
(en)
|
2011-06-01 |
2012-12-06 |
Merial Limited |
Needle-free administration of prrsv vaccines
|
WO2013025274A1
(en)
|
2011-08-12 |
2013-02-21 |
Merial Limited |
Vacuum -assisted preservation of biological products, in particular of vaccines
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
GB201118636D0
(en)
|
2011-10-28 |
2011-12-07 |
Oxford Biomedica Ltd |
Nucleotide sequence
|
WO2013093629A2
(en)
|
2011-12-20 |
2013-06-27 |
Netherlands Cancer Institute |
Modular vaccines, methods and compositions related thereto
|
GB201202516D0
(en)
|
2012-02-13 |
2012-03-28 |
Ucl Business Plc |
Materials and methods relating to packaging cell lines
|
WO2013138776A1
(en)
|
2012-03-16 |
2013-09-19 |
Merial Limited |
Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
|
US9347065B2
(en)
|
2012-03-29 |
2016-05-24 |
International Aids Vaccine Initiative |
Methods to improve vector expression and genetic stability
|
DK3889173T3
(da)
|
2013-02-15 |
2023-10-09 |
Bioverativ Therapeutics Inc |
Optimeret faktor viii-gen
|
EP2968514A1
(en)
|
2013-03-12 |
2016-01-20 |
Merial, Inc. |
Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
|
BR112015022189A2
(pt)
*
|
2013-03-13 |
2017-11-21 |
Katsura Misako |
microvesícula, método para produção e uso da mesma
|
GB201318804D0
(en)
|
2013-10-24 |
2013-12-11 |
Adaptimmune Ltd |
Vectors for transgene expression
|
CA2927712A1
(en)
|
2013-10-24 |
2015-04-30 |
Ospedale San Raffaele S.R.L. |
Method for the genetic modification of haematopoietic stem and progenitor cells (hspcs) and the use of genetically modified hspcs in gene therapy
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
JP7060324B2
(ja)
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ネオ抗原ワクチンによる併用療法
|
GB201407322D0
(en)
|
2014-04-25 |
2014-06-11 |
Ospedale San Raffaele |
Gene therapy
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
GB201412494D0
(en)
|
2014-07-14 |
2014-08-27 |
Ospedale San Raffaele And Fond Telethon |
Vector production
|
EP3215188A1
(en)
|
2014-11-03 |
2017-09-13 |
Merial, Inc. |
Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
EP3268044A2
(en)
|
2015-03-11 |
2018-01-17 |
The Broad Institute Inc. |
Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
|
CR20200476A
(es)
|
2015-05-20 |
2020-12-02 |
Dana Farber Cancer Inst Inc |
ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
|
TWI750122B
(zh)
|
2015-06-09 |
2021-12-21 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
MX2017016895A
(es)
|
2015-06-23 |
2018-04-10 |
Merial Inc |
Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso.
|
EP3380620B1
(en)
|
2015-11-23 |
2024-07-03 |
Novartis AG |
Optimized lentiviral transfer vectors and uses thereof
|
PT3383920T
(pt)
|
2015-11-30 |
2024-04-15 |
Univ California |
Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
|
PT3411478T
(pt)
|
2016-02-01 |
2022-09-13 |
Bioverativ Therapeutics Inc |
Genes do fator viii otimizados
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
US20190346442A1
(en)
|
2016-04-18 |
2019-11-14 |
The Broad Institute, Inc. |
Improved hla epitope prediction
|
WO2017197038A1
(en)
|
2016-05-10 |
2017-11-16 |
United States Government As Represented By The Department Of Veterans Affairs |
Lentiviral delivery of crispr/cas constructs that cleave genes essential for hiv-1 infection and replication
|
DK3455239T3
(da)
*
|
2016-05-13 |
2021-07-05 |
Flash Therapeutics |
Partikel til indkapsling af et genomteknisk system
|
IL265957B2
(en)
|
2016-10-12 |
2024-04-01 |
Bioverativ Usa Inc |
Anti-C1S antibodies and methods of using them
|
AU2017353939A1
(en)
|
2016-11-07 |
2019-06-06 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
US11434301B2
(en)
|
2016-11-11 |
2022-09-06 |
The Regents Of The University Of California |
Anti-CD46 antibodies and methods of use
|
WO2018129540A1
(en)
*
|
2017-01-09 |
2018-07-12 |
American Gene Technologies International Inc. |
Hiv immunotherapy with no pre-immunization step
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
WO2018148671A1
(en)
|
2017-02-12 |
2018-08-16 |
Neon Therapeutics, Inc. |
Hla-based methods and compositions and uses thereof
|
JP7277388B2
(ja)
|
2017-03-15 |
2023-05-18 |
オックスフォード バイオメディカ(ユーケー)リミテッド |
方法
|
GB201706394D0
(en)
|
2017-04-21 |
2017-06-07 |
Ospedale San Raffaele Srl |
Gene Therapy
|
EP3645044A4
(en)
|
2017-06-27 |
2021-04-28 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
|
CN111344011B
(zh)
|
2017-06-27 |
2024-01-26 |
纽洛可科学有限公司 |
抗fam19a5抗体用于治疗纤维化的用途
|
AU2018291081A1
(en)
|
2017-06-27 |
2020-01-16 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies for treating cancers
|
AU2018291082A1
(en)
|
2017-06-27 |
2020-01-16 |
Neuracle Science Co., Ltd. |
Anti-FAM19A5 antibodies and uses thereof
|
WO2019068854A1
(en)
|
2017-10-06 |
2019-04-11 |
Ospedale San Raffaele S.R.L. |
GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
|
TWI823868B
(zh)
|
2017-10-11 |
2023-12-01 |
美商生物維瑞提夫美國公司 |
誘導補體活性之方法
|
EP3696272A1
(en)
|
2017-12-22 |
2020-08-19 |
Oxford BioMedica (UK) Limited |
Retroviral vector
|
BR112020015228A2
(pt)
|
2018-02-01 |
2020-12-29 |
Bioverativ Therapeutics Inc. |
Uso de vetores lentivirais que expressam fator viii
|
KR20240001331A
(ko)
|
2018-04-24 |
2024-01-03 |
주식회사 뉴라클사이언스 |
신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
|
JP2021518761A
(ja)
|
2018-05-10 |
2021-08-05 |
ニューラクル サイエンス カンパニー リミテッド |
配列類似性19、メンバーa5抗体を有する抗ファミリー及びその使用方法
|
WO2019222403A2
(en)
|
2018-05-15 |
2019-11-21 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
US20210260216A1
(en)
|
2018-06-25 |
2021-08-26 |
Ospedale San Raffaele S.R.L. |
Gene therapy
|
MX2020013923A
(es)
|
2018-06-29 |
2021-03-29 |
Apitbio Inc |
Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
|
KR20210043574A
(ko)
|
2018-07-09 |
2021-04-21 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
푸소좀 조성물 및 이의 용도
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
AU2019358519A1
(en)
|
2018-10-11 |
2021-05-27 |
Fondazione Telethon Ets |
Selection by means of artificial transactivators
|
WO2020102485A1
(en)
|
2018-11-14 |
2020-05-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
JP2022507454A
(ja)
|
2018-11-14 |
2022-01-18 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
Cns送達のためのフソソーム組成物
|
JP2022507453A
(ja)
|
2018-11-14 |
2022-01-18 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
T細胞送達のためのフソソーム組成物
|
KR20210093950A
(ko)
|
2018-11-16 |
2021-07-28 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질 및 면역 관문 저해제의 조합으로 종양을 치료하는 방법
|
WO2020117992A1
(en)
*
|
2018-12-04 |
2020-06-11 |
The Broad Institute, Inc. |
Improved vector systems for cas protein and sgrna delivery, and uses therefor
|
WO2020118069A2
(en)
|
2018-12-06 |
2020-06-11 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor ix
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
EP3899954A4
(en)
|
2018-12-21 |
2022-09-14 |
BioNTech US Inc. |
METHODS AND SYSTEMS FOR PREDICTING HLA CLASS II SPECIFIC EPITOPES AND CHARACTERIZING CD4+ T CELLS
|
JP2022525136A
(ja)
|
2019-03-10 |
2022-05-11 |
サイオ ジーン セラピーズ インコーポレイテッド |
パーキンソン病を処置するための遺伝子治療組成物および方法
|
GB201905244D0
(en)
|
2019-04-12 |
2019-05-29 |
Ospedale San Raffaele |
Method for analysisng insertion sites
|
GB201905301D0
(en)
|
2019-04-15 |
2019-05-29 |
Ospedale San Raffaele Srl |
Gene therapy
|
GB201907493D0
(en)
|
2019-05-28 |
2019-07-10 |
Ospedale San Raffaele |
Agents and methods for treating viral infections
|
CA3152525A1
(en)
|
2019-09-03 |
2021-03-11 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
CA3152600A1
(en)
|
2019-09-30 |
2021-04-08 |
Andrew KROETSCH |
Lentiviral vector formulations
|
JP2023504593A
(ja)
|
2019-11-12 |
2023-02-06 |
オックスフォード バイオメディカ(ユーケー)リミテッド |
産生系
|
CN114945409A
(zh)
|
2020-01-13 |
2022-08-26 |
新免疫技术有限公司 |
用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法
|
WO2021151006A2
(en)
|
2020-01-22 |
2021-07-29 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
EP4093751A1
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
JP2023512657A
(ja)
|
2020-02-05 |
2023-03-28 |
ワシントン・ユニバーシティ |
Il-7タンパク質とcar保有免疫細胞の組み合わせで固形腫瘍を治療する方法
|
EP4103723A1
(en)
|
2020-02-13 |
2022-12-21 |
Oxford BioMedica (UK) Limited |
Production of lentiviral vectors
|
DE102020106710A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
KR20220154734A
(ko)
|
2020-03-13 |
2022-11-22 |
옥스포드 바이오메디카(유케이) 리미티드 |
렌티바이러스 벡터
|
EP4127144A1
(en)
|
2020-03-31 |
2023-02-08 |
Sana Biotechnology, Inc. |
Targeted lipid particles and compositions and uses thereof
|
CA3177006A1
(en)
|
2020-04-27 |
2022-10-26 |
University Of Iowa Research Foundation |
Compositions and methods for the treatment of cystic fibrosis
|
GB202007106D0
(en)
|
2020-05-14 |
2020-07-01 |
Ucl Business Plc |
Cyclosporine analogues
|
GB202007169D0
(en)
|
2020-05-14 |
2020-07-01 |
Ospedale San Raffaele Srl |
Epidermal growth factor receptor
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
BR112022026127A2
(pt)
|
2020-06-24 |
2023-01-17 |
Bioverativ Therapeutics Inc |
Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
|
GB202010009D0
(en)
|
2020-06-30 |
2020-08-12 |
Syncona Investment Man Ltd |
Vector
|
CN116419747A
(zh)
|
2020-08-07 |
2023-07-11 |
福蒂斯治疗公司 |
靶向cd46的免疫偶联物及其使用方法
|
WO2022047316A1
(en)
|
2020-08-28 |
2022-03-03 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
WO2022079054A1
(en)
|
2020-10-12 |
2022-04-21 |
Ospedale San Raffaele S.R.L. |
Replacement of rag1 for use in therapy
|
US20230398216A1
(en)
|
2020-10-22 |
2023-12-14 |
Lyell Immunopharma, Inc. |
Chimeric activation receptors
|
WO2022093718A1
(en)
|
2020-10-26 |
2022-05-05 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
WO2022094475A1
(en)
|
2020-11-02 |
2022-05-05 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
JP2023549112A
(ja)
|
2020-11-05 |
2023-11-22 |
ネオイミューンテック, インコーポレイテッド |
Il-7タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
GB202018657D0
(en)
|
2020-11-26 |
2021-01-13 |
Ospedale San Raffaele Srl |
Agents and methods for increasing liver immune response
|
GB202019108D0
(en)
|
2020-12-03 |
2021-01-20 |
Ospedale San Raffaele Srl |
Vector
|
KR20230142704A
(ko)
|
2020-12-14 |
2023-10-11 |
바이오엔테크 유에스 인크. |
암 면역요법을 위한 조직 특이적 항원
|
WO2022146891A2
(en)
|
2020-12-31 |
2022-07-07 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating car-t activity
|
AU2022206324A1
(en)
|
2021-01-11 |
2023-07-20 |
Sana Biotechnology, Inc. |
Use of cd8-targeted viral vectors
|
US20240101623A1
(en)
|
2021-02-15 |
2024-03-28 |
Ospedale San Raffaele S.R.L. |
Epigenetic silencing for treatment of cancer
|
GB202103470D0
(en)
|
2021-03-12 |
2021-04-28 |
Univ Bristol |
Promoter
|
CA3217247A1
(en)
|
2021-04-26 |
2022-11-03 |
Csl Behring L.L.C. |
Lentiviral vectors useful for the treatment of disease
|
AU2021202658A1
(en)
|
2021-04-28 |
2022-11-17 |
Fondazione Telethon |
Gene therapy
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2022251712A1
(en)
|
2021-05-28 |
2022-12-01 |
Sana Biotechnology, Inc. |
Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
|
WO2022256437A1
(en)
|
2021-06-02 |
2022-12-08 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
EP4370544A2
(en)
|
2021-07-14 |
2024-05-22 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
TW202321457A
(zh)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
靶向cd4之病毒載體之用途
|
WO2023056331A1
(en)
|
2021-09-30 |
2023-04-06 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
IL312062A
(en)
|
2021-10-12 |
2024-06-01 |
Fond Telethon Ets |
Polynucleotides useful for correcting mutations in the RAG1 gene
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
GB202114972D0
(en)
|
2021-10-19 |
2021-12-01 |
Ospedale San Raffaele Srl |
Gene therapy
|
WO2023077107A1
(en)
|
2021-10-29 |
2023-05-04 |
Sana Biotechnology, Inc. |
Methods and reagents for amplifying viral vector nucleic acid products
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
GB202117844D0
(en)
|
2021-12-09 |
2022-01-26 |
Oxford Biomedica Ltd |
Purification method
|
WO2023114949A1
(en)
|
2021-12-16 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and systems of particle production
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
TW202342498A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科融合醣蛋白
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
EP4209511A1
(en)
|
2022-01-05 |
2023-07-12 |
Gyala Therapeutics Sociedad Limitada |
Anti-cd84 antibodies amd chimeric antigen receptors
|
WO2023131657A1
(en)
|
2022-01-05 |
2023-07-13 |
Gyala Therapeutics Sociedad Limitada |
Anti-cd84 antibodies and chimeric antigen receptors
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
GB202204272D0
(en)
|
2022-03-25 |
2022-05-11 |
Ucl Business Ltd |
Method for engineering innate-like lymphocytes
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
WO2023198828A1
(en)
|
2022-04-13 |
2023-10-19 |
Universitat Autònoma De Barcelona |
Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
|
GB202206346D0
(en)
|
2022-04-29 |
2022-06-15 |
Ospedale San Raffaele Srl |
Gene therapy
|
GB202209098D0
(en)
|
2022-06-21 |
2022-08-10 |
Ucl Business Ltd |
Cyclosporine analogues
|
WO2024003578A1
(en)
|
2022-07-01 |
2024-01-04 |
The University Of Bristol |
Vector comprising a sequence encoding an anti-tnf antibody and an inflammation-inducible promoter
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
WO2024008950A1
(en)
|
2022-07-08 |
2024-01-11 |
Ospedale San Raffaele S.R.L. |
Transgene cassettes
|
WO2024015892A1
(en)
|
2022-07-13 |
2024-01-18 |
The Broad Institute, Inc. |
Hla-ii immunopeptidome methods and systems for antigen discovery
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024026490A1
(en)
|
2022-07-28 |
2024-02-01 |
Sqz Biotechnologies Company |
Polynucleotides encoding linked antigens and uses thereof
|
WO2024033544A1
(en)
|
2022-08-12 |
2024-02-15 |
Ospedale San Raffaele S.R.L. |
Deglycosylation of native glycoproteins expressed on a tumor cell surface
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
WO2024100294A1
(en)
|
2022-11-11 |
2024-05-16 |
Ospedale San Raffaele S.R.L. |
Cdh17 car
|
GB202217332D0
(en)
|
2022-11-18 |
2023-01-04 |
Univ Bristol |
Methods
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|